HANGZHOU, CHINA — Chinese cochlear implant maker, Nurotron Biotechnology, announced last month that it has expanded into the European market, with the recent implantation of a Spanish man and a Polish woman. The company now has a presence in 9 countries throughout Asia, Latin America and now, Europe.
Following implantation surgery at the Medical University in Bialystok, Poland, doctors activated Nurotron’s flagship Venus Cochlear Implant System last month in a 54-year-old woman with severe, progressive hearing loss.
In Badalona, Spain, surgeons at Hospital Universitari Germans Trias I Pujol, with assistance from Nurotron’s experts, successfully implanted a 47-year-old man who suffered from rapidly progressing bilateral hearing loss. His system was then activated in late December.
Company Quietly Expanding
With Nurotron’s latest announcement of the European implants, it extends the growth of the company to 9 countries, including: Bolivia, China, Colombia, India, Peru, Poland, Spain, Turkey and Venezuela.
“Nurotron’s entry into Europe continues to address the demand for safe, reliable cochlear implants around the world.” –Chu Li, Nurotron CEO
With the company’s entry into Europe, it will be competing in a highly competitive market directly against major hearing industry players, such as Sonova (Advanced Bionics), William Demant (Oticon Medical, Nuerelec), Med-El, and Cochlear.
Founded in 2006, Nurotron is headquartered in Hangzhou, China. However, the growing company maintains its research and development center in Irvine, California, and manufacturing facilities in China.
